Abstract:Genetic diseases affecting the retina can result in partial or complete loss of visual function. Leber's Congenital Amaurosis (LCA) is a rare blinding disease, usually inherited in an autosomally recessive manner, with no cure. Retinal gene therapy has been shown to improve vision in LCA patients caused by mutations in the RPE65 gene (LCA2). However, little is known about how activity in central visual pathways is affected by the disease or by subsequent gene therapy. Functional MRI was used to assess retinal signal transmission in cortical and subcortical visual structures before and one year after retinal intervention. The fMRI paradigm consisted of 15-second blocks of flickering (8-Hz) black and white checkerboards interleaved with 15 seconds of blank (black) screen. Visual activation in the brain was assessed using the general linear model, with multiple comparisons corrected using the false discovery rate method. Response to visual stimulation through untreated eyes of LCA2 patients showed heightened fMRI responses in the superior colliculus (SC) and diminished activities in the lateral geniculate nucleus (LGN) compared to controls, indicating a shift in the patients' visual processing towards the retinotectal pathway (RT). Following gene therapy, stimuli presented to the treated eye elicited significantly stronger fMRI responses in the LGN and primary visual cortex, indicating some reengagement of the geniculostriate pathway (GS) pathway. Across patients, the post-treatment LGN fMRI responses correlated significantly with performance on a clinical test measuring light sensitivity. Our results demonstrate that the low vision observed in LCA2 patients involves a shift in visual processing toward the retinotectal pathway, and that gene therapy partially reinstates visual transmission through the GS pathway. This selective boosting of retinal output through the GS pathway and its correlation to improved visual performance, following several years of degenerative retinal disease, is striking. However, while retinal gene therapy and other ocular interventions have given hope to RPE65 patients, it may take years before development of therapies tailored to treat the diseases in other low vision patients are available. Our demonstration of a shift toward the RT pathway in these patients may spur the development of new tools and rehabilitation strategies to help maximize the use of residual visual abilities and augment experience-dependent plasticity.

LEBER CONGENITAL AMAUROSIS DUE TO CEP290 MUTATIONS-SEVERE VISION IMPAIRMENT WITH A HIGH UNMET MEDICAL NEED: A Review

Clinical and genetic studies for a cohort of patients with Leber congenital amaurosis

Diagnostic and Therapeutic Consequences

The Clinical Findings, Pathogenic Variants, and Gene Therapy Qualifications Found in a Leber Congenital Amaurosis Phenotypic Spectrum Patient Cohort

CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype

A Novel CEP290 Disease-Causing Variant Identified in a Patient with Leber Congenital Amaurosis Using a Medical Diagnostic Panel Sequencing.

Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10

Genetic and clinical findings in a Chinese cohort with Leber congenital amaurosis and early onset severe retinal dystrophy

GUCY2D Gene Loss-of-Function Mutations Responsible for Leber Congenital Amaurosis 1

Union Makes Strength: A Worldwide Collaborative Genetic and Clinical Study to Provide A Comprehensive Survey of Rd3 Mutations and Delineate the Associated Phenotype

A novel pathogenic CRB1 variant presenting as Leber Congenital Amaurosis 8 and evaluation of gene editing feasibility

The Pathogenicity of Novel GUCY2D Mutations in Leber Congenital Amaurosis 1 Assessed by HPLC-MS/MS.

Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report

Molecular Genetics of Leber Congenital Amaurosis in Chinese: New Data from 66 Probands and Mutation Overview of 159 Probands

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

Phenotype-genotype Correlation with Sanger Sequencing Identified Retinol Dehydrogenase 12 (RDH12) Compound Heterozygous Variants in a Chinese Family with Leber Congenital Amaurosis.

Exome Sequencing Identifies NMNAT1 Mutations As a Cause of Leber Congenital Amaurosis

Central visual pathways affected by degenerative retinal disease before and after gene therapy

Differential Proteomics And Functional Research Following Gene Therapy In A Mouse Model Of Leber Congenital Amaurosis

Mutation Analysis Of Leber Congenital Amaurosis-Associated Genes In Patients With Retinitis Pigmentosa

Mutations in NMNAT1 Cause Leber Congenital Amaurosis and Identify a New Disease Pathway for Retinal Degeneration